TTD | Drug: D03KLF

Drug General Information
Drug ID	D03KLF
Former ID	DIB004495
Drug Name	MDX-1203
Synonyms	Alkylating agent-antibody conjugate (cancer), Medarex
Drug Type	Antibody
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[522737]
Company	Medarex Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	C1C(=O)N(C(=O)C1*)CCCC(=O)NCCN[C@H](C(=O)N[C@H](C(=O)Nc<br />1ccc(C(=O)Nc2ccc3[nH]c(cc3c2)C(=O)N2c3cc(c4ccccc4c3[C@@<br />H](C2)CCl)OC(=O)N2CCN(CC2)C)cc1)CCCNC(=O)N)C(C)C
Target and Pathway
Target(s)	CD70	Target Info		[549691]
KEGG Pathway	Cytokine-cytokine receptor interaction
NetPath Pathway	IL2 Signaling Pathway
	TNFalpha Signaling Pathway
	RANKL Signaling Pathway
Reactome	TNFs bind their physiological receptors
References
Ref 522737	ClinicalTrials.gov (NCT00944905) Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). U.S. National Institutes of Health.
Ref 549691	J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information